Ready, steady, ’mo!

MEN AROUND THE WORLD ARE COV­ER­ING THEIR UP­PER LIPS IN GLORY IN SUP­PORT OF THE MOVEM­BER MEN’S HEALTH INI­TIA­TIVE

Destiny Man - - HEALTH SPY -

About 5,6 mil­lion men glob­ally face life with a pros­trate can­cer di­ag­no­sis and 330 000 live with tes­tic­u­lar can­cer. In SA, prostate can­cer is the sec­ond lead­ing cause of can­cer death, while male sui­cide ac­counts for ap­prox­i­mately 18 deaths a day.

To raise aware­ness and funds, men around the world will once again be cul­ti­vat­ing han­dle­bars, Tom Sel­lecks and other lip-warm­ers over the 30 days of No­vem­ber. Those who can’t grow mous­taches and women are en­cour­aged to join the cam­paign by sup­port­ing “’Mo Bros”, or­gan­is­ing events and spread­ing the word.

The Movem­ber move­ment was first es­tab­lished in 2003 in Aus­tralia to raise aware­ness of men’s health is­sues and be­came an of­fi­cial char­ity in 2004. Since then, it’s spread to 21 coun­tries across the globe, with funds be­ing di­rected to more than 1 200 men’s health projects. These in­clude ini­tia­tives aimed at pre­vent­ing tes­tic­u­lar and prostate can­cer, sui­cide and men­tal ill­ness. The foun­da­tion, which is the largest non-gov­ern­men­tal fun­der of men’s health pro­grammes in the world, aims to re­duce the num­ber of pre­ma­ture male deaths by 25% by 2030.

Ear­lier this year, the Movem­ber Foun­da­tion be­came the first char­ity to launch an ex­clu­sive doc­u­men­tary series on In­sta­gram. “We cre­ated this series to share real-life ex­pe­ri­ences of men who deal with the chal­lenges of prostate and tes­tic­u­lar can­cer ev­ery day, and to share the im­por­tance of qual­ity of life with both the Movem­ber com­mu­nity and the larger In­sta­gram net­work,” says

Jon Ak­er­man, the foun­da­tion’s Global Dig­i­tal Direc­tor. “With In­sta­gram’s launch of IGTV to share longer-form con­tent, it’s the ideal plat­form to tell more emo­tional, en­gag­ing sto­ries.”

Newspapers in English

Newspapers from South Africa

© PressReader. All rights reserved.